NCT07487545尚未招募1 期
A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of SSS67 in Healthy Adult Participants Via Single Intravenous Infusion
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 52
- 试验地点
- 2
- 主要终点
- Incidence and severity of AEs
研究概览
简要总结
This is a randomized, double-blind, placebo-controlled, single ascending dose phase I clinical study to evaluate the safety, tolerability, PK, preliminary PD and immunogenicity of SSS67 in healthy adult participants after single intravenous infusion.
The primary objective is to assess the safety and tolerability of SSS67 following single ascending doses.
The secondary objectives are to characterize the PK, PD, and anti-drug antibody (ADA) profiles of SSS67 after single administration.
The exploratory objective is to evaluate changes in body weight, waist circumference, and other related metabolic parameters following a single dose of SSS67.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Participants aged 18 to 65 years (inclusive), regardless of gender.
- •Participate in the clinical trial voluntarily and provide informed consent form.
- •At screening, body weight ≥ 50 kg for males and ≥ 45 kg for females. Body Mass Index (BMI) must be between 18.5 and 32 kg/m² (inclusive).
- •At screening, the following must be within normal ranges or assessed by the investigator as abnormal but not clinically significant: Vital signs、Physical examination、12-lead electrocardiogram (ECG)、Chest X-ray (posteroanterior view) or lung computed tomography (CT)、Ultrasound (abdominal, urological, and gynecological [for females only])、Clinical laboratory tests (including hematology, urinalysis, blood biochemistry, coagulation, serum virolgy and thyroid function).
- •Female participants with childbearing potential and male participants (and their female partners) must agree to take highly effective contraceptive measures and have no plan of childbearing, sperm donation, or egg donation from screening through at least 6 months after the last dose of investigational drug.
- •Able to understand and comply with protocol requirements.
排除标准
- •History of significant drug or food allergies; or known clinically significant hypersensitivity to the study intervention or related compounds.
- •History of risk factors for torsades de pointes (e.g., heart failure/cardiomyopathy or family history of long QT syndrome), uncorrected hypokalemia or hypomagnesemia (one retest may be allowed per Investigator's judgment), or QT (QTcF) interval >450 ms.
- •Any clinically significant medical condition or illness that could compromise participant safety or interfere with study results.
- •History of any malignancy within the past 5 years, except for basal cell carcinoma, squamous cell carcinoma in situ, or cervical carcinoma in situ th with no evidence of metastatic disease for 3 years.
- •Known concomitant conditions affecting skeletal muscle, or use of any medications or supplements known to influence muscle anabolism/catabolism within 3 months prior to screening.
- •History of gastrointestinal surgery resulting in malabsorption, or chronic use of medications that s directly affect gastrointestinal motility. Examples: history of bariatric surgery/procedures (e.g., gastric banding), use of medications/products deemed by the investigator to cause weight change and affect weight assessment within 3 months prior to dosing, or intention to use weight-loss drugs during the study.
- •Use of any prescription drugs or over-the-counter medications, herbal medicines, or dietary supplements within 4 weeks prior to screening (participants may be enrolled if the investigator confirms the time interval between last use and the first dose in this trial is >5 half-lives of the drug).
- •Use of drugs potentially affecting follicle-stimulating hormone (FSH) levels within 90 days prior to screening, or planned use during the study.
- •Regular weightlifting, bodybuilding, or strength training aimed at increasing muscle mass.
结局指标
主要结局
Incidence and severity of AEs
时间窗: Day 57
次要结局
- bone resorption biomarker(Day 57)
- Peak concentration(Day 57)
- Incidence of antidrug antibodies (ADAs) to SSS67 over time(Day 57)
- Bone formation biomarker(Day 57)
研究者
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
1 期
A First-in-human, Single-ascending-dose Study of IBI3033 in Healthy ParticipantsNCT07311226Innovent Biologics (Suzhou) Co. Ltd.32
招募中
1 期
A Study to Find a Suitable Dose of Exl-111 for Further ResearchNCT07356713Excellergy Inc.70
已完成
1 期
A First-in-Human Study of KINE-101 in Healthy VolunteersNCT07343323Kine Sciences Co., Ltd.40
招募中
1 期
Evaluate the Safety, Tolerability, PK, and PD of JMT206 Injection in Healthy ParticipantsNCT07419698Shanghai JMT-Bio Inc.44
已完成
1 期
A Phase 1 MAD Study of KINE-101 in Healthy VolunteersNCT07324642Kine Sciences Co., Ltd.24